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Most authors who publish in the Journal of Investigative Dermatology and most members of the Journal’s two 
affiliated societies—the Society for Investigative 
Dermatology (SID) and the European Society 
for Dermatological Research (ESDR)—conduct 
research that impacts health. This is evident in 
the titles of the articles published in JID and in the 
abstracts and talks presented at the annual meet-
ings of these societies. That impact may be direct, 
as in studies of outcome instruments for pem-
phigus (Rosenbach et al., 2009); indirect, as in 
reports about dendritic cells residing in squamous 
cell carcinomas (Bluth et al., 2009); or remote, as 
in the impact of protein kinase C-α on keratino-
cyte growth arrest (Jerome-Morais et al., 2009).
It should not be surprising that the efforts of 
basic researchers may impact human health, 
because the mission of the major funding 
source for biomedical research in the United 
States—the National Institutes of Health 
(NIH)—is highly congruent with these obser-
vations: “NIH is the steward of medical and 
behavioral research for the Nation. Its mission 
is science in pursuit of fundamental knowl-
edge about the nature and behavior of living 
systems and the application of that knowledge 
to extend healthy life and reduce the burdens 
of illness and disability” (http://www.nih.gov/
about/index.html#mission).
Taking these assertions one step further, the 
target of funding, and therefore the target of 
biomedical research, is people with disease, 
more commonly known as patients. In sum, it’s 
all about patients.
But scholarly journals lack descriptions of 
what it is like to be a patient, to be ill at ease 
about one’s health, to have disease. Although 
many investigators who contribute to the sci-
entific literature about skin and skin disease 
know very much about their patients and what 
it is like to have a disease such as pemphigus, 
squamous cell carcinoma, or psoriasis, they 
rarely write about the impact of that disease on 
the lives of their patients.
Although there have been exceptions to 
this tendency, such as the JID Symposium 
Proceedings issue on the burden of skin dis-
ease (March 2004), we assert that there is a gap 
between the impact of a disease for patients 
and the content of scientific reports. To begin 
to address this gap, we have designated 2010 
“The Year of the Patient,” and we dedicate 
these issues of JID to patients. Our intent is to 
describe to the scientific world at large the bur-
den that patients with skin disease bear.
In the coming year we will describe the 
impact of patient advocacy organizations, such 
as the National Psoriasis Foundation and the 
Alopecia Areata Foundation, which provide 
considerable support, not only for the scientif-
ic enterprise but also for individuals with these 
diseases. Moreover, 16 advocacy organizations 
have combined their efforts and resources in 
a collective organization now known as the 
Coalition of Skin Diseases (http://www.coali-
tionofskindiseases.org); member organizations 
pool their efforts while at the same time pro-
viding resources to meet their own interests. 
We applaud their efforts.
Every year the Coalition of Skin Diseases, 
in association with members of SID and the 
American Academy of Dermatology, partici-
pate in an advocacy meeting in Washington, 
DC. Representatives of these organizations 
visit the legislative offices of their congressional 
districts and states on Capitol Hill. They 
describe patients’ experiences, and they advo-
cate for the goals of the NIH. As a long-time 
participant, I have observed that the “staff-
ers” are interested primarily in the Coalition 
advocates and voters, with the scientists a dis-
tant second. Medical scientists and practicing 
physicians should enter the room last. In sum, 
it’s all about patients.
Several years ago, staff of the SID and mem-
bers of the Coalition created art and poetry 
exhibitions that were displayed at each SID 
Annual Meeting for four years. The works on 
display provided extraordinary insight into the 
impact of disease on the lives of patients. In 
2010, work from these artists will be featured 
on the cover of JID. Moreover, up to six pages 
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in scope from those with direct impact on health, includ-
ing clinical research, epidemiology, and health services 
research, to fundamental laboratory observations about 
mechanisms of cellular function. We will continue to pub-
lish the best papers that are submitted, assuming that they 
provide scientific insight into skin and skin disease.
Paul R. Bergstresser
Editor
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of editorial space will be devoted to poetic descriptions 
of disease written by patients. We assure our readers that 
the intensity and creativity displayed in these contributions 
will fortify your creative spirit as you pursue your research 
endeavors.
We will remember John Updike for his contributions to 
the public understanding of what it is like to have psoriasis. 
We will encourage Commentary authors, in addition to put-
ting the scientific impact of an article into perspective, to 
describe, perhaps only briefly, how the research might impact 
human health. In selected Editorials we will draw attention 
to the critical role of patients in the biomedical enterprise. 
Because it’s all about patients.
Finally, what will we not do? This year’s editorial empha-
sis on the impact of disease on patients and the contribu-
tions of patients to research does not signal a shift in the 
Journal’s stated scope. As before, submissions may range 
